Identification and Targeting of Internalizing Breast Tumor Receptors for Immunotherapy
Yu Zhou,Helen Q. Huang,Lindsay T. McDonald,Hao Zou,James D. Marks
IF: 11.2
2005-01-01
Cancer Research
Abstract:567 Breast tumors can be histologically classified into basal, luminal, and mesenchymal cell types which vary in prognosis and response to different therapies. Expression array analysis reveals significant differences in the genes up and down regulated in these three tumor types. We hypothesized that these differences would result in a different pattern of cell surface receptor overexpression which could be exploited for antibody based molecular therapies. Such therapies could potentially target most members of a given tumor type. To test this hypothesis, we selected monovalent and multivalent non-immune single chain Fv(scFv) phage antibody libraries on a panel of luminal (SKBR3, MCF7, T47D, MDA-MB-453 and MDA-MB-361) and mesenchymal (MDA-MB-231 and BT549) breast tumor cell lines. We employed a strategy developed in the lab that selects phage antibodies that trigger receptor mediated endocytosis. The resulting antibodies can thus be employed therapeutically not only as naked antibodies but also to deliver targeted therapies including immunotoxins, immunoliposomes, antibody-drug conjugates and for the targeted delivery of genes or viral DNA into cells. After two rounds of selection on the target cell line, large panels of antibodies were isolated which could be classified into three groups: 1) non specific antibodies (bind all cell types tested, 50% of antibodies); 2) cell line specific (bind only the cell line used for selection, 5% of antibodies); and 3) cell type specific (bind most, or all, members of a given breast tumor cell type, 45% of antibodies. For example, after selection of phage libraries on MDA-MB-231 cells, at least 8 unique antibodies were generated which bound all mesenchymal cell lines analyzed (MDA-MB-231, MDA-MB-231-guise, BT549, Hs578T) but not luminal cell lines (SKBR3, MCF7, T47D, MDA-MB-453) These preliminary results suggest that a large panel of antibodies against native tumor surface proteins can be developed through direct selection of phage antibody libraries on breast tumor cell lines. The resulting antibodies appear largely cell type specific and may be a route to antibodies which can be used for intracellular drug delivery and to identify the antigens bound. It is likely that a subset of antibodies may also directly inhibit growth or induce apoptosis. Studies are ongoing to: 1) profile the antibodies on a larger panel of mesenchymal and luminal cell lines; 2) determine whether the antibodies are efficiently internalized; and 3) determine whether the antibodies have direct antiproliferative activity.